Small Business Innovation Research

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Retrieved on: 
Monday, March 11, 2024
Bangladesh Technical Education Board, SBIR, Research, Toxicity, FDA, Food, Conference, Small Business Innovation Research, Safety, Therapy, Pharmacokinetics, Patient, Glutamate (neurotransmitter), Ageing, Pharmaceutical industry

NEW HAVEN, Conn., March 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company, announced that its lead compound, ALX-001, is ready to proceed to Phase 2 clinical development in Alzheimer’s and Parkinson’s disease. This announcement was made in conjunction with the presentation of positive findings from the company’s Phase 1b multiple ascending dose study at the AD/PD™ 2024 Conference in Lisbon. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases.

Key Points: 
  • This announcement was made in conjunction with the presentation of positive findings from the company’s Phase 1b multiple ascending dose study at the AD/PD™ 2024 Conference in Lisbon.
  • ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases.
  • The multiple ascending dose study (NCT05804383) examined the safety, tolerability and pharmacokinetics of twice-daily oral doses of ALX-001 in 32 heathy adult participants aged 50-80.
  • Allyx Therapeutics has initiated a 28-day safety study of ALX-001 in Alzheimer’s disease patients (NCT05804383) and is initiating a study in Parkinson’s disease patients.

NAPIGEN, Inc. Secures U.S. Patent, Awarded USDA SBIR Grant

Retrieved on: 
Monday, March 11, 2024
SBIR, CRISPR, Biotechnology, Climate, Farmer, Patent, Plant, Cell, Business development, Small Business Innovation Research, Mitochondrion, Plastid, RNA, Genome, United, Intellectual property, Food security, Pollen, DNA

The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.

Key Points: 
  • The patented claims of US11920140 are directed to methods for altering the genomes of mitochondria or plastids.
  • The mitochondria, also known as the powerhouses of cells, are critical components of plant, fungal, algal, and animal cells.
  • It is the third SBIR grant the company has received since its founding in 2016.
  • NAPIGEN, Inc. expects to complete a Series A financing this year to advance partnerships with agricultural companies to bring products to market.

Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

Retrieved on: 
Tuesday, March 5, 2024
Bangladesh Technical Education Board, SBIR, Research, New Drug Application, Synapse, FDA, Food, Conference, Small Business Innovation Research, Safety, Therapy, Pharmacokinetics, Patient, IND, Glutamate (neurotransmitter), Pharmaceutical industry

A 28-day safety study of ALX-001 in Parkinson’s disease patients will be initiated in Q1 2024.

Key Points: 
  • A 28-day safety study of ALX-001 in Parkinson’s disease patients will be initiated in Q1 2024.
  • “We are working with urgency to understand how the unique mechanism of action of ALX-001 at mGluR5, which preserves and protects synapses, can introduce meaningful clinical benefits for people living with Alzheimer’s disease and Parkinson’s disease,” commented Allyx Therapeutics co-founder and CEO Stephen Bloch, M.D.
  • As studies in Parkinson’s disease begin, the company will continue to advance clinical development of ALX-001 in Alzheimer’s disease, which is funded through grants from the National Institutes of Health and other Alzheimer’s disease research nonprofit organizations.
  • Fox Foundation for Parkinson’s Research contributes to research efforts around the potential of ALX-001, enabling our work to move into clinical research without delay,” commented Tim Siegert, Ph.D., chief operating officer and co-founder of Allyx Therapeutics.

Argonne Upgrade Lets Data Portal Users Get NERDE about Economic Resilience

Retrieved on: 
Thursday, February 29, 2024
Software, Research, Other Energy, Professional Services, Internet, Data Management, Energy, Technology, White House, Federal Government, Data Analytics, Science, Labor, Public Policy, Government, United States census, Economic development, Small business, EDCI, Gross domestic product, Argonne National Laboratory, EDA, Small Business Innovation Research, Climate change, Patent, Employment, Statistics, DOE, Community, Partnership, Management

Community leaders and administrators now have a more powerful tool for understanding their communities’ economic strengths and vulnerabilities, thanks to the newly enhanced National Economic Resilience Data Explorer (NERDE).

Key Points: 
  • Community leaders and administrators now have a more powerful tool for understanding their communities’ economic strengths and vulnerabilities, thanks to the newly enhanced National Economic Resilience Data Explorer (NERDE).
  • The online data portal’s enhanced second edition makes it easier for users to create economic development plans, improve resilience, and apply for economic assistance and grants.
  • NERDE first launched as a partnership between the U.S. Department of Energy’s (DOE) Argonne National Laboratory and the Department of Commerce’s Economic Development Administration (EDA) in 2022.
  • “We learned that NERDE has been highly useful for grant applications, comprehensive economic development strategies , and market research.

Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Health, Genetics, Stem Cells, Pharmaceutical, Korean, Therapy, Bangladesh Technical Education Board, ALS, Multimedia, Small business, NIH, FDA, US FDA, Food, Sale, Drug discovery, Small Business Innovation Research, Quality control, Charcot–Marie–Tooth disease, University, Chronic pain, CMT, Neuromuscular junction, Patient, NCATS, MOU, NMJ, Partnership, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240222795787/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240222795787/en/
    Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay (Photo: Business Wire)
    BoT is renowned for its therapeutic applications, including the treatment of chronic pain, autonomic disorders, congenital neuromuscular conditions, and cosmetic enhancements.
  • The project has supported Curi Bio’s development of a next-generation 3D human neuromuscular junction model used for disease modeling, for pharmaceutical and cosmetics potency assays, and for testing broad pathogenicity.
  • The project will deliver a functional potency assay for botox research and manufacture in a turnkey, scalable format.
  • With this MOU, Genetox shows its commitment to making Curi Bio’s NMJ-based potency assay a key part of BOTAONE’s manufacturing, quality control, and product release processes.

Fusion Start-Up Wins Air Force SBIR Contract to Prototype Lower Cost Nuclear Effects Testing

Retrieved on: 
Wednesday, February 28, 2024
Transfer, AFWERX, Engineering, RET, Advisory board, SBIR, Air force, DAF, Small business, Government, Air Force Research Laboratory, Fuse, Lead, USAF, Small Business Innovation Research, STTR, 3D printing

PALO ALTO, Calif., Feb. 28, 2024 /PRNewswire/ -- Fuse -- an innovative company delivering engineering breakthroughs related to fusion power -- today announced that it has been selected for an AFWERX Small Business Innovation Research (SBIR) contract to address the most pressing challenges in the Department of the Air Force related to nuclear effects testing.

Key Points: 
  • "Fuse is delivering fusion engineering breakthroughs at lower cost and faster speed than others," said JC Btaiche, Founder and CEO of Fuse.
  • We are proud to partner with the Air Force Research Laboratory and AFWERX to efficiently and cost-effectively offer nuclear effects testing to provide Air Force operators greater tactical flexibility and survivability."
  • "Fuse brings much needed nuclear effects testing to an underserved market, particularly given the dramatic growth in the commercial and government space."
  • With several advanced pulsed-power prototypes already demonstrated, Fuse will look to prototype additional solutions in the electro-magnetic spectrum for nuclear effects testing and system hardening while lowering costs and providing Air Force operators greater tactical flexibility and survivability.

U.S. Air Force Awards Soaak Technologies' Second Contract to Enhance Airmen Performance with Innovative Sound Technology

Retrieved on: 
Wednesday, February 21, 2024
Transfer, AFWERX, SBIR, Air force, DAF, Small business, Government, Air Force Research Laboratory, AFRL, Policy, Small Business Innovation Research, STTR

Soaak Technologies is developing advanced mobile and web applications, tailored for the DAF's unique operational needs.

Key Points: 
  • Soaak Technologies is developing advanced mobile and web applications, tailored for the DAF's unique operational needs.
  • These applications are created to improve mission readiness and cognitive resilience using Soaak's proprietary sound frequency technology , addressing the crucial requirement of maintaining peak mental and physical states in demanding environments.
  • By integrating Soaak's proprietary technology, this project is set to advance health tech innovation and the operational efficacy of service members.
  • Our proprietary technology represents a groundbreaking passive and pharmacology-free method to enhance warfighter performance, resilience, and overall well-being," said Aaron Fournier, President of Soaak Digital.

RocketStar Announces Newest SBIR Contract Win to Develop Low Probability of Interception Communication Software for the Military

Retrieved on: 
Wednesday, February 14, 2024
Transfer, AFWERX, SBIR, Air force, DAF, Small business, Noise, Sahul Shelf, Probability, Integration, Air Force Research Laboratory, United States Space Force, Communication, Commercial, Safety, COTS, USSF, LPI, Quantum computing, Software, Small Business Innovation Research, STTR, Communications satellite

In December, RocketStar continued its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.

Key Points: 
  • In December, RocketStar continued its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.
  • In today’s increasingly contested space domain, ensuring secure and reliable communication during launch and throughout satellite operations is paramount.
  • Near-peer adversaries such as China and Russia have the capability to disrupt, detect, and infiltrate communication channels utilized for space operations.
  • "We are eager to apply our unique LPI software and advance RocketStar's efforts to help the DAF secure our nation."

Blue Marble Health and Allergy & Asthma Network Announce SBIR Award to Pilot Innovative BREATHE Virtual Asthma Coaching Platform

Retrieved on: 
Tuesday, February 13, 2024
Bangladesh Technical Education Board, SBIR, Research, Health equity, NIH, Asthma, Heart rate, Self-management, Small Business Innovation Research, Exercise, Smartphone, Allergy, COPD, Pharmaceutical industry

NIH awarded the SBIR funding to Blue Marble Health to develop the BREATHE (BRinging Asthma Education, Assessments, and Exercise To Everyone) virtual self-management platform.

Key Points: 
  • NIH awarded the SBIR funding to Blue Marble Health to develop the BREATHE (BRinging Asthma Education, Assessments, and Exercise To Everyone) virtual self-management platform.
  • The Blue Marble Health Platform is designed to support Allergy & Asthma Network's 6-week asthma self-management program with 1-on-1 certified asthma educators.
  • The Blue Marble Health Asthma Self-Management Platform serves as the virtual asthma coaching platform for the Trusted Messengers Community Outreach Program, the signature health equity program of Allergy & Asthma Network.
  • The Blue Marble Health's Asthma Self-Management Platform is the first commercially available digital asthma self-management platform available for people in under-resourced communities and those experiencing long-term health disparities.

America’s Seed Fund Road Tour Visits Florida and Puerto Rico to Engage Startups and Small Businesses Working on Innovative, High-impact Ideas

Retrieved on: 
Monday, February 12, 2024
Transfer, Investment, Small Business Innovation Research, SBIR, Entrepreneurship, Invention, SBA, FAST, Research, STTR, Renewable energy

The Road Tour helps connect underrepresented groups in innovation and entrepreneurship with sources of capital via the agency’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.

Key Points: 
  • The Road Tour helps connect underrepresented groups in innovation and entrepreneurship with sources of capital via the agency’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
  • America’s Seed Fund , comprised of the SBIR/STTR programs, supports next-generation research & development (R&D) and commercialization of innovations and provides over $4 billion each year in non-dilutive funding from 11 participating federal agencies.
  • For more detailed information on the America’s Seed Fund Road Tour stops and registration to attend in person, visit https://www.americasseedfund.us/road-tour .
  • For more information about America’s Seed Fund (SBIR/STTR) programs, please visit www.sbir.gov .